Evaluation of medicinal products indicated for treatment of bacterial infections

  • Email
  • Help
Current effective version

Revision 2 - Adopted guideline

Currently under revision - see below

Reference numberCPMP/EWP/558/95 Rev. 2
Published09/01/2012
Effective from15/01/20012
KeywordsNon-inferiority studies, superiority studies, susceptibility testing, pharmacokinetic/pharmacodynamic (PK/PD) relationship, bacteraemia, febrile neutropenia, eradication of carriage, drug-resistant organisms; paediatric investigation plan (PIP)
DescriptionThis document considers the microbiological and clinical data required to support indications, dose regimens and durations of therapy for antibacterial agents. It also addresses the layout and wording of some sections of the summary of product characteristics. Read together with the addendum to specifically address the clinical development of new agents to treat disease due to Mycobacterium tuberculosis and the addendum to address indication-specific clinical data requirements.


Document history

Revision 3

In progress

Concept paper

Published: 13/06/2018

Deadline for comments: 13/09/2018

Revision 2

Current version

Adopted guideline


 

Draft guideline


 

Concept paper

In operation: 15/01/2012-present


 

Published: 25/03/2010


 

Published: 19/02/2009


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more